[Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011292:Premedication; D013431:Sulfates / Q000627:therapeutic use
D013431:Sulfates; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D002262:Carboxy-Lyases
Effekte der Zusatzmedikation von Amantadinsulfat bei L-Dopa-vorbehandelten Parkinson-Kranken.